SCHEMBL4715734

SCHEMBL4715734

Fc1cccc(-c2cc(Nc3cccc4cnccc34)ncn2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 3/20 0.45
EGFR P00533 2/20 0.43
GRM5 P41594 1/20 0.43
FYN P06241 1/20 0.42
ALDH1A1 P00352 3/20 0.41
MAPT P10636 3/20 0.41
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
THRB P10828 1/20 0.41
HTT P42858 1/20 0.41
BLM P54132 1/20 0.41
MAP4K4 O95819 1/20 0.41
PDE4B Q07343 1/20 0.41
KMO O15229 1/20 0.41
KDM4E B2RXH2 2/20 0.40
ABL1 P00519 3/20 0.39
BCR P11274 3/20 0.39
CCR4 P51679 1/20 0.38
P2RX7 Q99572 1/20 0.38
ERBB2 P04626 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4716052 0.88 PDE4B (0.51) TRPV1ALDH1A1MAPTKMT2AMEN1
SCHEMBL4718686 0.86 ALDH1A1 (0.48) TRPV1ALDH1A1MAPTKMT2AMEN1
SCHEMBL4718692 0.86 TRPV1 (0.49) TRPV1ALDH1A1MAPTPDE4BKDM4E
SCHEMBL4715943 0.86 TRPV1 (0.55) TRPV1FYNKMOABL1BCR
SCHEMBL4719637 0.85 TRPV1 (0.48) TRPV1ALDH1A1MAPTKMT2AMEN1
SCHEMBL4718544 0.84 TGFBR1 (0.43) TRPV1ALDH1A1MAPTKMT2AMEN1
SCHEMBL4718454 0.84 MAPK1 (0.45) TRPV1ALDH1A1MAPTKMT2AMEN1
SCHEMBL4718526 0.84 TRPV1 (0.41) TRPV1ALDH1A1MAPTKMT2AMEN1
SCHEMBL4718622 0.84 PDE4B (0.41) TRPV1ALDH1A1MAPTKMT2AMEN1
SCHEMBL4717106 0.83 TRPV1 (0.43) TRPV1ALDH1A1MAPTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7442701-B2 Amino-heterocycles as VR-1 antagonists for treating pain MERCK SHARP & DOHME LTD. (GB) 2008-10-28 US disclosed
EP-1562934-B1 AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME (GB) 2008-03-26 EP disclosed
US-20060040947-A1 Amino-heterocycles as vr-1 antagonists for treating pain MERCK SHARP & DOHME LTD. (GB) 2006-02-23 US disclosed
EP-1562934-A1 AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LTD. (GB) 2005-08-17 EP disclosed
WO-2004046133-A1 AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LIMITED (GB) 2004-06-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060040947-A1 Amino-heterocycles as vr-1 antagonists for treating pain OPRL1, CNR1, GPR6 TRPV1 40/4885EGFR 1164/4885GRM5 258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.